DCTD Programs
Last Updated: 12/14/2017
DCTD's Translational Research Program Announces Fiscal Year 2017 SPORE Grantees
The Translational Research Program (TRP) announced its successfully competed FY2017 Specialized Programs of Research Excellence (SPORE) grantees. The SPORE program uses the P50 grant funding mechanism to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2017 grantees, there are now 53 funded SPOREs located at academic centers in 22 states.
Principal Investigator | Institution | Type of Cancer |
---|---|---|
Robert Bast, MD and Anil Sood, MD | University of TX, MD Anderson Cancer Center | Ovarian |
Benjamin Ebert, MD, PhD and Richard Stone, MD | Brigham and Women's Hospital | Leukemia |
*Helen Heslop, MD, DSc and Malcolm Brenner, MD, PhD | Baylor College of Medicine | Lymphoma |
Linda Liau, MD, PhD | UCLA | Brain |
*Sanford Markowitz, MD, PhD | Case Western Reserve University | Gastrointestinal |
Mark Rubin, MD | Weill Cornell | Prostate |
*George Weiner, MD and Thomas Witzig, MD | University of Iowa | Lymphoma |
*Grant Renewal
The goals of the SPORE program include:
- Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
- Determining the biological basis for clinical observations
- Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
- Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
- Promoting pilot projects and career enhancement of researchers new to translational research
- Supporting research in high incidence and rare cancers
- Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective
Contact TRP staff for more information on the SPORE program.